Ophthalmology. Retina最新文献

{"title":"Moyamoya Disease Increased the Risk of Retinal Vascular Occlusion","authors":"Min Seok Kim MD, MSc ,&nbsp;Seonghee Nam MS ,&nbsp;Si Un Lee MD, MSc ,&nbsp;Sang Jun Park MD, PhD ,&nbsp;Se Joon Woo MD, PhD ,&nbsp;Jeongwoo Lee BA ,&nbsp;Kwangsic Joo MD, PhD","doi":"10.1016/j.oret.2024.10.013","DOIUrl":"10.1016/j.oret.2024.10.013","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the risk of retinal vascular occlusion in patients with Moyamoya disease (MMD).</div></div><div><h3>Design</h3><div>Retrospective, longitudinal cohort study using the Korean National Health Insurance Service database.</div></div><div><h3>Participants</h3><div>Newly diagnosed MMD patients (n = 34 627), who were diagnosed between 2004 and 2022, and their propensity score matched controls (n = 136 945) were included.</div></div><div><h3>Methods</h3><div>We identified retinal vascular occlusion events using diagnostic codes for central retinal artery occlusion, other retinal artery occlusion, and retinal vein occlusion. After a washout period from 2002 to 2003, information on the diagnosis of retinal vascular occlusion was extracted in both MMD and control group during the follow-up period. The association between MMD and the risk of subsequent retinal vascular occlusion was investigated using a time-dependent Cox proportional hazard model and Kaplan–Meier survival analysis with log-rank test adjusted for age, sex, and comorbidities.</div></div><div><h3>Main Outcome Measures</h3><div>Hazard ratios (HRs) and 95% confidence intervals (CIs) for retinal vascular occlusion development according to the MMD.</div></div><div><h3>Results</h3><div>Moyamoya disease was associated with an increased risk of subsequent retinal vascular occlusion even after adjusting for confounding variables (HR, 1.22; 95% CI, 1.09–1.36). Among the subtypes of retinal vascular occlusion, central retinal artery occlusion showed a highest HR (2.23; 95% CI, 1.35–3.7). Incidence probability of retinal vascular occlusion was significantly higher among MMD patients than controls (<em>P</em> &lt; 0.001, log-rank test).</div></div><div><h3>Conclusions</h3><div>In this nationwide population-based cohort study, patients with MMD in Korea had an elevated risk of retinal vascular occlusion, suggesting that the MMD is one of the risk factors for retinal vascular occlusion.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages 386-391"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Muayad et al.: Influence of common medications on diabetic macular edema in type 2 diabetes mellitus (Ophthalmol Retina. 2024 Dec 5:S2468-6530(24)00582-7. doi: 10.1016/j.oret.2024.12.006. Online ahead of print.)","authors":"Wan-Ju Annabelle Lee MD, PhD","doi":"10.1016/j.oret.2025.01.001","DOIUrl":"10.1016/j.oret.2025.01.001","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages e28-e29"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endophthalmitis Incidence after Intravitreal Injection of Anti-VEGF Agents with Povidone-Iodine versus Aqueous Chlorhexidine Antisepsis.","authors":"Brandon Bates, John Fitzpatrick, Caroline Rosanky, Jared Moon, Edward Wood, Philip Storey","doi":"10.1016/j.oret.2025.03.022","DOIUrl":"10.1016/j.oret.2025.03.022","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the incidence of postinjection endophthalmitis (PIE) after intravitreal injection (IVI) of anti-VEGF agents in eyes prepared with topical 5% povidone-iodine (PI) or 0.05% aqueous chlorhexidine (AqCHX) as antisepsis.</p><p><strong>Design: </strong>Retrospective, single-center, comparative cohort study.</p><p><strong>Participants: </strong>Individuals who received ≥1 intravitreal anti-VEGF injection with use of PI or AqCHX as antisepsis.</p><p><strong>Methods: </strong>For all patients receiving intravitreal anti-VEGF injections at Austin Retina Associates between March 1, 2015 and November 1, 2023, all injections and cases of suspected PIE were identified with billing codes and confirmed with review of electronic medical record data. Eyes that presented after injection with pain or decreased vision warranting treatment with intravitreal antibiotics were considered suspected PIE cases. Eyes were grouped based on preparation with PI or AqCHX.</p><p><strong>Main outcome measures: </strong>The primary outcomes were incidence of suspected and culture-positive PIE and visual acuity (VA) at 3 months postendophthalmitis.</p><p><strong>Results: </strong>A total of 302 474 IVIs were administered during the study period. Within the PI group, 59 cases of suspected PIE occurred after 267 190 injections (0.022%; 1 in 4529 injections) compared with 5 cases after 35 284 injections (0.014%; 1 in 7057 injections) in the AqCHX group (P = 0.34). For the PI group, there were 10 culture-positive PIE cases (0.0037%, 1 in 26 719 injections) compared with 0 cases in the AqCHX group (P = 0.25). At 3 months postinfection, average VA in the PI group was 0.97 (∼20/200) and 1.4 (∼20/500) in the AqCHX group (P = 0.41). When controlling for prefilled syringe status, there was no difference in rates of PIE between antisepsis groups (P = 0.23).</p><p><strong>Conclusions: </strong>The incidence of endophthalmitis after IVI is low, with no difference in the rates of infection with eyes prepared with topical PI compared with AqCHX. Topical AqCHX has similar efficacy to PI for the prevention of endophthalmitis after IVI.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epstein-Barr Virus Lymphoproliferative Disorder in a Patient with Acute Lymphoblastic Leukemia.","authors":"Lydia Zhong, Michael Ip, Kirk K Hou","doi":"10.1016/j.oret.2025.02.026","DOIUrl":"https://doi.org/10.1016/j.oret.2025.02.026","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.","authors":"Gabriela Grimaldi, Aude Ambresin, Isabel B Pfister, Christin Schild, Christina Plasencia, Katja Hatz, Richard Stillenmunkes, Marion R Munk, Arianna Paris, Moreno Menghini, Dmitri Artemiev, Andreas Ebneter, Jennifer Cattaneo, Eva C de Oliveira Figueiredo, Chiara M Eandi, Jacqueline Fröhlich, Nicolas Feltgen, Tahm Spitznagel, Gábor Márk Somfai, Mariano Cozzi, Sandrine Zweifel, Andreas Weinberger, Justus G Garweg","doi":"10.1016/j.oret.2025.03.015","DOIUrl":"10.1016/j.oret.2025.03.015","url":null,"abstract":"<p><strong>Purpose: </strong>To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pretreated neovascular age-related macular degeneration (nAMD).</p><p><strong>Design: </strong>Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.</p><p><strong>Subjects: </strong>We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-VEGF therapy and followed for a minimum of 12 months between May 1, 2022, and October 30, 2024.</p><p><strong>Methods: </strong>Demographic characteristics, baseline functional and OCT findings, treatment history, and outcomes at 12 months after switch to faricimab were extracted from the patients' electronic case report forms.</p><p><strong>Main outcome measures: </strong>Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals, and safety signals.</p><p><strong>Results: </strong>Twelve months after switch, mean BCVA remained unchanged, whereas mean CST decreased from 315.3 to 263.9 μm (P < 0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301) = 0.24; P < 0.01). After 12 months, 169 (47.9%) eyes demonstrated the absence of RF compared with 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, and extended treatment intervals (≥12 week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.</p><p><strong>Conclusions: </strong>Switching to faricimab in pretreated nAMD led to sustained anatomic improvements and stabilization of BCVA, with a substantial reduction in RF compared with baseline. Our results suggest the potential benefits of this switching strategy based on real-world data.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Counselor Integration Improves Genetic Eye Disease Diagnostics.","authors":"Mark Lindquist, Jennifer Cech, Amanda Peterson, Jennifer Huey, Debarshi Mustafi","doi":"10.1016/j.oret.2025.03.016","DOIUrl":"10.1016/j.oret.2025.03.016","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"United States versus Non-United States Retreatment Rates after Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity.","authors":"Nimesh A Patel, Luis A Acaba-Berrocal, Sandra Hoyek, Celine Chaaya, Kenneth C Fan, Maria Ana Martinez-Castellanos, Caroline R Baumal, Clio Armitage Harper, Audina M Berrocal","doi":"10.1016/j.oret.2025.03.013","DOIUrl":"10.1016/j.oret.2025.03.013","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-VEGF Use for Conditions without US Food and Drug Administration Approval.","authors":"Ravi Parikh, Elias H Kahan, Casey Zhang, Rhiya Mittal, Arjun Watane, Flora C Lum, Scott M Friedman","doi":"10.1016/j.oret.2025.03.014","DOIUrl":"10.1016/j.oret.2025.03.014","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmic Artery Chemosurgery for Retinoblastoma Babies Less than 3 Months Old or under 6-kg Weight.","authors":"David H Abramson, Jasmine H Francis, Jared Knopman, Ira J Dunkel, Yves Pierre Gobin","doi":"10.1016/j.oret.2025.03.008","DOIUrl":"10.1016/j.oret.2025.03.008","url":null,"abstract":"<p><strong>Objective: </strong>To determine the feasibility, safety, and efficacy of ophthalmic artery chemosurgery (OAC) for very young children who have unilateral and bilateral retinoblastoma.</p><p><strong>Design: </strong>Retrospective, consecutive review of all children with retinoblastoma (unilateral and bilateral) treated with OAC in the first 3 months of life or, if weighing <6 kg, treated at the Memorial Sloan Kettering Cancer Center.</p><p><strong>Participants: </strong>All children with retinoblastoma (unilateral or bilateral) treated with OAC (17 patients) in the first 3 months of life or weighing <6 kg.</p><p><strong>Methods: </strong>Ophthalmic artery chemosurgery delivered by microcatheter inserted in the femoral artery and through the internal carotid artery. Combinations of melphalan, carboplatin, and topotecan were delivered in 60 sessions via the ophthalmic artery in 17 patients.</p><p><strong>Main outcome measures: </strong>Ocular salvage, serial electroretinograms, patient survival, second cancers, fever/neutropenia, transfusion of any blood product, groin bleeding or femoral artery occlusion, and anesthetic complications.</p><p><strong>Results: </strong>Seventeen retinoblastoma patients under the age of 3 months or weighing <6 kg were successfully canulated and treated a total of 60 times (11 bilateral patients and 6 unilateral patients) with combinations of Melphalan, Carboplatin, and Topotecan. All patients are alive; the mean follow-up 4 years. No patient developed metastatic disease, second cancer, or trilateral retinoblastoma and all eyes were salvaged. There were no cases of chemotherapy induced fever/neutropenia or need for transfusion of any blood product. Electroretinogram was not impaired by treatment, significant improvement in 30Hz function was seen (P = 0.02; mean before 61 μV, after 71 μV, SEM: 5.25 vs. 5.82).</p><p><strong>Conclusions: </strong>Very young children (<3 months old and <6 kg weight) with unilateral or bilateral retinoblastoma can be safely and effectively treated with OAC (intra-arterial chemotherapy) without significant complications even though the majority had advanced intraocular disease (Reese-Ellsworth Vb or International Classification of Retinoblastoma \"D\" and \"E\"). This includes treating both eyes in the same session and as young as 5 weeks and weighing 3.6 kg. This eliminates the need for systemic chemotherapy, which is well known to be toxic to the youngest children.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Clinical Features of Polypoidal Choroidal Vasculopathy in Black Patients: A Cross-Sectional Study and a Comprehensive Review.","authors":"Adam Lazrak, Martin Bonnafous, Albert Jean-Charles, Katia Ouamrane, Alizée Tabouillot, Yanice Chaoui-Boudghane, Harold Merle","doi":"10.1016/j.oret.2025.02.030","DOIUrl":"10.1016/j.oret.2025.02.030","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the clinical and angiographic presentation of polypoidal choroidal vasculopathy (PCV) in a large cohort of Black patients.</p><p><strong>Design: </strong>We conducted a descriptive cross-sectional analysis.</p><p><strong>Participants: </strong>Out of 283 patients followed for PCV in our department, 167 cases were confirmed by indocyanine green angiography (ICGA). The remaining patients lacked ICGA imaging. Among the 167 confirmed cases, 57 patients were excluded due to significant ophthalmological comorbidities, leaving 160 affected eyes in 110 patients for analysis.</p><p><strong>Methods: </strong>We reviewed the most recent retinophotography, OCT, fluorescein, and ICGA images in our database. All analyzed patients were followed and underwent their examinations at the University Hospital Center of Martinique, a referral center in Fort de France primarily serving a Black population. An exploratory analysis of choroidal features was made in those who underwent enhanced depth imaging spectral-domain OCT. In parallel, a literature review on PCV was performed to contextualize our findings.</p><p><strong>Main outcome measures: </strong>We measured visual acuity, sex ratio, patient age, characteristics of exudative phenomena, polyp location, and PCV type according to Kawamura classification.</p><p><strong>Results: </strong>Most patients were women (62.7%), with an average age of 72.2 ± 10.1 years. Among the 160 eyes, 81.9% exhibited idiopathic type 2 PCV and 52.4% showed peripapillary polyp distribution. The mean visual acuity was 0.29 ± 0.3 logarithm of the minimum angle of resolution. Soft drusen were present in 15% of eyes, and 44.5% of patients had bilateral involvement. Black patients seem to have distinctive PCV characteristics compared with other ethnic groups, with a low incidence of macular polyps (23.1%), a high incidence of peripapillary polyps (52.4%), and high incidence of bilateral involvement (42.8%).</p><p><strong>Conclusions: </strong>This is the largest series of Afro-descendant patients with PCV ever described in the literature. Polypoidal choroidal vasculopathy in our population is primarily type 2 PCV according to Kawamura's classification, predominantly affecting women, often bilateral, with a preferentially extramacular location of the polyps. These observations may be explained by the fact that PCV in these patients is not the result of neovascularization but rather linked to a generalized disease of the choroid, such as pachychoroid.</p><p><strong>Financial disclosure(s): </strong>The authors have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}